Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Inclacumab fails, and osivelotor is on hold.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Shortly after ponsegromab, visugromab is to start phase 2/3.
Meanwhile, ASK Pharm challenges Hutchmed in cMet.